Literature DB >> 22488248

Lipoprotein(a), interleukin-10, C-reactive protein, and 8-year outcome after percutaneous coronary intervention.

Isabella Kardys1, Rohit M Oemrawsingh, I Patrick Kay, Gregory T Jones, Sally P A McCormick, Joost Daemen, Robert Jan Van Geuns, Eric Boersma, Ron T Van Domburg, Patrick W Serruys.   

Abstract

BACKGROUND: This prospective study investigated the association between preprocedural biomarker levels and incident major adverse cardiac events (MACE) in complex patients undergoing percutaneous coronary intervention (PCI) with sirolimus-eluting stenting. HYPOTHESIS: Lipoprotein(a) (Lp[a]), interleukin-10 (IL-10), and high-sensitivity C-reactive protein (CRP) have long-term prognostic value in patients undergoing PCI.
METHODS: Between April 2002 and February 2003, 161 patients were included in the study. Blood was drawn before the procedure, and biomarkers were measured. Patients were followed-up for MACE (death, nonfatal myocardial infarction, and repeat revascularization). Cox proportional hazard models were used to determine risk of MACE for tertiles of biomarkers. Both 1-year and long-term follow-up (median, 6 years; maximum, 8 years) were evaluated.
RESULTS: Mean age was 59 years, and 68% were men. During long-term follow-up, 72 MACE occurred (overall crude cumulative incidence: 45% [95% confidence interval (CI): 37%-52%]). Lp(a) was associated with a higher 1-year risk of MACE, with an adjusted hazard ratio (HR) of 3.1 (95% CI: 1.1-8.6) for the highest vs the lowest tertile. This association weakened and lost significance with long-term follow-up. IL-10 showed a tendency toward an association with MACE. The 1-year HR was 2.1 (95% CI: 0.92-5.0). Long-term follow-up rendered a similar result. The association of CRP with MACE did not reach statistical significance at 1-year follow-up. However, CRP was associated with long-term risk of MACE, with an HR of 1.9 (95% CI: 1.0-3.5).
CONCLUSIONS: In this prospective study, preprocedural Lp(a) level was associated with short-term prognosis after PCI. The preprocedural CRP level was associated with long-term prognosis after PCI.
© 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22488248      PMCID: PMC6652555          DOI: 10.1002/clc.21988

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  14 in total

1.  Association of lipoprotein(a) with long-term mortality following coronary angiography or percutaneous coronary intervention.

Authors:  Zhe Feng; Hua-Long Li; Wei-Jie Bei; Xiao-Sheng Guo; Kun Wang; Shi-Xin Yi; De-Mou Luo; Xi-da Li; Shi-Qun Chen; Peng Ran; Peng-Yuan Chen; Sheikh Mohammed Shariful Islam; Ji-Yan Chen; Yong Liu; Ying-Ling Zhou
Journal:  Clin Cardiol       Date:  2017-04-26       Impact factor: 2.882

2.  Plasma urokinase antigen and C-reactive protein predict angina recurrence after coronary angioplasty.

Authors:  Yelena Parfyonova; Irina Alekseeva; Olga Plekhanova; Alexander Deev; Elena Titaeva; Anatoly Dobrovolsky; Zufar Gabbasov; Anatoly Lyakishev; Vsevolod Tkachuk
Journal:  Heart Vessels       Date:  2013-09-22       Impact factor: 2.037

3.  The association of lipoprotein(a) with incident heart failure hospitalization: Atherosclerosis Risk in Communities study.

Authors:  Anandita Agarwala; Yashashwi Pokharel; Anum Saeed; Wensheng Sun; Salim S Virani; Vijay Nambi; Chiadi Ndumele; Eyal Shahar; Gerardo Heiss; Eric Boerwinkle; Suma Konety; Ron C Hoogeveen; Christie M Ballantyne
Journal:  Atherosclerosis       Date:  2017-05-12       Impact factor: 5.162

4.  Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia.

Authors:  Bing Sun; Yuan Xie; Jinfa Jiang; Yiping Wang; Xiaolin Xu; Cuimei Zhao; Feifei Huang
Journal:  Lipids Health Dis       Date:  2015-04-14       Impact factor: 3.876

5.  Evaluation of Early Atherosclerosis Markers in Patients with Inflammatory Bowel Disease.

Authors:  Yusuf Üstün; Serta Kilincalp; Şahin Çoban; Yusuf Coşkun; İlhami Yüksel; Aydan Ongun; İrfan Soykan; Mehmet Bektaş; Murat Törüner; Hülya Çetinkaya; Necati Örmeci
Journal:  Med Sci Monit       Date:  2016-10-24

6.  Cohort profile of BIOMArCS: the BIOMarker study to identify the Acute risk of a Coronary Syndrome-a prospective multicentre biomarker study conducted in the Netherlands.

Authors:  Rohit M Oemrawsingh; K Martijn Akkerhuis; Victor A Umans; Bas Kietselaer; Carl Schotborgh; Eelko Ronner; Timo Lenderink; Anho Liem; David Haitsma; Pim van der Harst; Folkert W Asselbergs; Arthur Maas; Anton J Oude Ophuis; Ben Ilmer; Rene Dijkgraaf; Robbert-Jan de Winter; S Hong Kie The; Alexander J Wardeh; Walter Hermans; Etienne Cramer; Ron H van Schaik; Imo E Hoefer; Pieter A Doevendans; Maarten L Simoons; Eric Boersma
Journal:  BMJ Open       Date:  2016-12-23       Impact factor: 2.692

7.  Impact of Lipoprotein (a) on Long-Term Outcomes in Patients with Coronary Artery Disease Treated with Statin After a First Percutaneous Coronary Intervention.

Authors:  Satoru Suwa; Manabu Ogita; Katsumi Miyauchi; Taketo Sonoda; Hirokazu Konishi; Shuta Tsuboi; Hideki Wada; Ryo Naito; Tomotaka Dohi; Takatoshi Kasai; Shinya Okazaki; Kikuo Isoda; Hiroyuki Daida
Journal:  J Atheroscler Thromb       Date:  2017-03-17       Impact factor: 4.928

8.  Lack of association between lipoprotein(a) genetic variants and subsequent cardiovascular events in Chinese Han patients with coronary artery disease after percutaneous coronary intervention.

Authors:  Zhi-Gen Li; Guang Li; Ying-Ling Zhou; Zhu-Jun Chen; Jun-Qing Yang; Ying Zhang; Shuo Sun; Shi-Long Zhong
Journal:  Lipids Health Dis       Date:  2013-08-27       Impact factor: 3.876

Review 9.  Lipoprotein(a): a promising marker for residual cardiovascular risk assessment.

Authors:  Anping Cai; Liwen Li; Ying Zhang; Yujin Mo; Weiyi Mai; Yingling Zhou
Journal:  Dis Markers       Date:  2013-10-22       Impact factor: 3.434

Review 10.  The relationship between Lp(a) and CVD outcomes: a systematic review.

Authors:  Carol A Forbes; Ruben G W Quek; Sohan Deshpande; Gill Worthy; Robert Wolff; Lisa Stirk; Jos Kleijnen; Shravanthi R Gandra; Stephen Djedjos; Nathan D Wong
Journal:  Lipids Health Dis       Date:  2016-05-17       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.